π¬ New in-body CAR T therapy helps autoimmune diseases
An experimental in vivo CAR T therapy called JY231 showed promise in a small early-stage trial for neurologic autoimmune disorders. The therapy was administered to 16 patients across MS, MOGAD, and others at Tongji Hospital in Wuhan, China. After 6 months, patients showed reduced disability and improved function in various conditions. This method bypasses complex manufacturing and chemotherapy, making treatment potentially more accessible. Investigators plan to further study its effectiveness and safety profile moving forward. π§